welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies
source: Pharmacotherapy
year: 2017
authors: Reinig AM, Mirzaei S, Berlau DJ
summary/abstract:Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disease that primarily affects young males. Patients with DMD are unable to produce dystrophin, a crucial protein found in myocytes, leading to a loss of muscle support and integrity. Corticosteroids are the standard supportive treatment for DMD; however, there is a high demand to expand the number of safe, effective pharmacologic options. Recently a surge of new therapeutics for DMD is offering hope to patients. A variety of these new medications, such as stop codon readthrough agents, exon-skipping agents, and utrophin modulators, aim to replace dystrophin in myocytes. Other new therapeutics aim to prevent or repair muscle damage caused by the absence of dystrophin. This review provides an update on the medications being investigated in DMD.
organization: Regis University Rueckert-Hartman College for Health ProfessionsDOI: 10.1002/phar.1909
read more full text source
rareRelated
-
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Results of North Star Ambulatory Assessments (NSAA) in the Phase 3 Ataluren Confirmatory Trial in Patients with Nons...Objective: Examine the efficacy of atal...
-
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene TherapyPfizer Inc. announced that its investiga...
-
Boy with muscular dystrophy writes heartfelt note to Scottish leaderMichael Young, 9, wrote a letter to Scot...
-
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
-
Archived drug prevents Duchenne muscular dystrophy muscle loss in miceA drug that showed promise in clinical t...